Xenon Pharmaceuticals (STU:XP0) Cyclically Adjusted PS Ratio: (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:XP0 Xenon Pharmaceuticals Inc STU:XP0
27 GF Score
Price €51.50
GF Value €0.14
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Xenon Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Xenon Pharmaceuticals  (STU:XP0) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Xenon Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Xenon Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Xenon Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenon Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Xenon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Xenon Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:XP0 vs PTCT, CGON, LGND: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Xenon Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenon Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


STU:XP0
27GF Score
Xenon Pharmaceuticals Inc STU:XP0
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenon Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Xenon Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Xenon Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/133.5265*133.5265
=0.000

Current CPI (Jun. 2026) = 133.5265.

Xenon Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.024 101.765 0.031
201612 0.020 101.449 0.026
201703 0.001 102.634 0.001
201706 0.001 103.029 0.001
201709 0.012 103.345 0.016
201712 0.001 103.345 0.001
201803 0.000 105.004 0.000
201806 0.000 105.557 0.000
201809 0.000 105.636 0.000
201812 0.000 105.399 0.000
201903 0.000 106.979 0.000
201906 0.000 107.690 0.000
201909 0.123 107.611 0.153
201912 0.113 107.769 0.140
202003 0.193 107.927 0.239
202006 0.340 108.401 0.419
202009 0.159 108.164 0.196
202012 0.121 108.559 0.149
202103 0.099 110.298 0.120
202106 0.044 111.720 0.053
202109 0.163 112.905 0.193
202112 0.062 113.774 0.073
202203 0.145 117.646 0.165
202206 0.009 120.806 0.010
202209 0.002 120.648 0.002
202212 0.000 120.964 0.000
202303 0.000 122.702 0.000
202306 0.000 124.203 0.000
202309 0.000 125.230 0.000
202312 0.000 125.072 0.000
202403 0.000 126.258 0.000
202406 0.000 127.522 0.000
202409 0.000 127.285 0.000
202412 0.000 127.364 0.000
202503 0.088 129.181 0.091
202506 0.000 129.892 0.000
202509 0.000 130.287 0.000
202512 0.000 130.366 0.000
202603 0.000 132.262 0.000
202606 0.000 133.527 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Xenon Pharmaceuticals (STU:XP0) Overvalued in 2026?

Based on GuruFocus' analysis, Xenon Pharmaceuticals stock appears to be overvalued. The current stock price of €51.50 is trading 36685.7% above its estimated GF Value™ of €0.14. GuruFocus considers Xenon Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:XP0:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.14 vs. price of €51.50 (36685.7% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the STU:XP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xenon Pharmaceuticals Business Description

Other Exchanges XENE:USA
Address 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
27GF Score

Get the complete analysis for STU:XP0

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.50
Price
€0.14
GF Value